Navidea Biopharmaceuticals, Inc.
| NYSE MKT: NAVB
Navidea Biopharmaceuticals, Inc. develops and commercializes precision diagnostics and radiopharmaceutical agents, which are intended to improve diagnostic accuracy, clinical decision-making and patient care. Its current radiopharmaceutical development programs include: Lymphoseek, AZD4694 and RIGScan agents, which are used in treating various tumor cancers. The company's primary focus in to improve surgery outcomes by using market-leading gamma detection devices in combination with radiopharmaceutical agents. The company was founded in 1983 and is headquartered in Dublin, OH.